Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies

Mao, Ren; Xiao, Yinglian; Gao, Xiang; Chen, Baili; He, Yao; Yang, Li; Hu, Pinjin; Chen, Minhu

doi:10.1002/ibd.22861

Cited by 249 publications

(181 citation statements)

References 32 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…Several recent meta-analyses confirmed that in adults and children, specificity is sometimes lower [45][46][47]. High levels of fecal calprotectin were found in some other gastrointestinal tract disorders and patients treated with non-steroidal anti-inflammatory drugs or proton pump inhibitors (Table 3) [44,45,48].…”

Section: Diagnostic Value Of Fecal Calprotectin In Ibdmentioning

confidence: 90%

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Manceau

Chicha-Cattoir²,

Puy

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are chronic diseases that result from the inflammation of the intestinal wall, suspected in any patient presenting with intestinal symptoms. Until recently, the diagnosis was mainly based on both clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive, and inexpensive biological assay is mandatory not only in diagnosis but also in evolutionary and therapeutic monitoring. To date, the fecal calprotectin is the most documented in this perspective. This marker allows the discrimination between functional and organic bowel processes with good performance. The determination of the fecal calprotectin level contributes to the evaluation of the degree of disease activity and to monitoring of therapeutic response.

show abstract

Section: Diagnostic Value Of Fecal Calprotectin In Ibdmentioning

confidence: 90%

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Manceau

Chicha-Cattoir²,

Puy

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…168 Calprotectin can also be used to predict relapse. 169 Calprotectin is also useful in children, as a non-invasive guide to mucosal inflammation and disease activity in previously diagnosed IBD, 170,171 in an admittedly small series of teenagers with IBD, examined clinical activity indices (PUCAI and PCDAI) CRP and FC for predicting relapse. 172 Calprotectin was more useful than clinical scores but CRP was not helpful.…”

Section: Implications Of Wider Use Of Calprotectinmentioning

confidence: 99%

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Waugh

Cummins²,

Royle³

et al. 2013

Health Technology Assessment

227

199

View full text Add to dashboard Cite

“…In a meta-analysis the area under the receiver operating characteristic (ROC) curve was 0.97, with an optimal cut-off value of 50 mcg/g that yielded 93% sensitivity and 94% specificity in discriminating IBD from IBS [22] . Further on, calprotectin levels correlate very well with endoscopic activity [23][24][25][26][27] , predict occurrence of a flare [28] and are capable of predicting response to treatment [27,[29][30][31] . However, calprotectin also rises in other situations, such as with non-steroidal antiinflammatory drugs (NSAIDs) use, and we lack a cut-off point that defines remission reliably [32] .…”

Section: How Do I Know That Ibd Is In Remission?mentioning

confidence: 96%

Diagnosis and management of functional symptoms in inflammatory bowel disease in remission

Teruel

Garrido

Mesonero

2016

WJGPT

View full text Add to dashboard Cite

it in the present work. We describe a problematic that comprises physiopathological uncertainties, diagnostic difficulties, as IBS-like symptoms are very similar to those produced by an inflammatory flare, and the necessity of appropriate management of these patients, who, although in remission, have impaired quality of life. Ultimately, from almost a philosophical point of view, the presence of IBS-like symptoms in IBD patients in remission supposes a challenge to the traditional functional-organic dichotomy, suggesting the need for a change of paradigm. Core tip: Many inflammatory bowel disease patients in remission suffer from ongoing gastrointestinal symptoms that resemble those of irritable bowel syndrome and that hinder their quality of life. We review the pathogenesis of these symptoms, their prevalence and the best management strategies. Author contributions: All authors contributed equally to this work. Conflict-of-interest statement:The authors declare no conflicts of interest. AbstractInflammatory bowel disease (IBD) patients in remission may suffer from gastrointestinal symptoms that resemble irritable bowel syndrome (IBS). Knowledge on this issue has increased considerably in the last decade, and it is our intention to review and summarize REVIEWSubmit a

show abstract

Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies

Abstract: As a simple and noninvasive marker, FC is useful to predict relapse in quiescent IBD patients.

Cited by 249 publications

References 32 publications

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

Diagnosis and management of functional symptoms in inflammatory bowel disease in remission

Contact Info

Product

Resources

About